Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Geisbert

Showing results (271-280 of 279) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 279 results.
Scientific Reports|April 14, 2018
Field validation of recombinant antigen immunoassays for diagnosis of Lassa feverMatthew L Boisen, Jessica N Hartnett, Jeffrey G Shaffer, et al.
Scientific Reports|September 30, 2020
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineagesMegan L Heinrich, Matthew L Boisen, Diana K S Nelson, et al.
Nature Communications|May 11, 2016
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsJames E Robinson, Kathryn M Hastie, Robert W Cross, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Plos Neglected Tropical Diseases|March 22, 2014
Lassa fever in post-conflict sierra leoneJeffrey G Shaffer, Donald S Grant, John S Schieffelin, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
The Journal of Infectious Diseases|July 13, 2016
An Outbreak of Ebola Virus Disease in the Lassa Fever ZoneAugustine Goba, S Humarr Khan, Mbalu Fonnie, et al.
Pageof 28

Showing results (271-280 of 279) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
Scientific Reports|April 14, 2018
Field validation of recombinant antigen immunoassays for diagnosis of Lassa feverMatthew L Boisen, Jessica N Hartnett, Jeffrey G Shaffer, et al.
Scientific Reports|September 30, 2020
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineagesMegan L Heinrich, Matthew L Boisen, Diana K S Nelson, et al.
Nature Communications|May 11, 2016
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsJames E Robinson, Kathryn M Hastie, Robert W Cross, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Plos Neglected Tropical Diseases|March 22, 2014
Lassa fever in post-conflict sierra leoneJeffrey G Shaffer, Donald S Grant, John S Schieffelin, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
The Journal of Infectious Diseases|July 13, 2016
An Outbreak of Ebola Virus Disease in the Lassa Fever ZoneAugustine Goba, S Humarr Khan, Mbalu Fonnie, et al.
Pageof 28